Cargando…
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
BACKGROUND AND PURPOSE: The SARS‐COV‐2 pandemic and the global spread of coronavirus disease 2019 (COVID‐19) urgently call for efficient and safe antiviral treatment strategies. A straightforward approach to speed up drug development at lower costs is drug repurposing. Here, we investigated the ther...
Autores principales: | Schloer, Sebastian, Brunotte, Linda, Mecate‐Zambrano, Angeles, Zheng, Shuyu, Tang, Jing, Ludwig, Stephan, Rescher, Ursula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251190/ https://www.ncbi.nlm.nih.gov/pubmed/33825201 http://dx.doi.org/10.1111/bph.15418 |
Ejemplares similares
-
Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
por: Brunotte, Linda, et al.
Publicado: (2021) -
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine
por: Schloer, Sebastian, et al.
Publicado: (2020) -
The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo
por: Schloer, Sebastian, et al.
Publicado: (2019) -
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection
por: Schloer, Sebastian, et al.
Publicado: (2020) -
Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro
por: Kummer, Susann, et al.
Publicado: (2022)